study team noted. In one trial, “a second RSV vaccine 
dose administered one year after the initial dose may 
have provided further benefit during season three, 
but the trial was not specifically designed to compare 
one-dose vs. two-dose regimens in this way, limiting 
inferences about long-term benefits of additional 
vaccination.”
The findings add urgency to ongoing discussions 
about whether immunocompromised patients, a sub-
stantial subpopulation at VAMCs, should receive 
booster doses, and at what intervals. No such rec-
ommendation currently exists from the Centers for 
Disease Control and Prevention’s Advisory Committee 
on Immunization Practices.
ACP Weighs In: Who Should Get Vaccinated?
The American College of Physicians (ACP) has also 
weighed in on RSV vaccine use, issuing rapid practice 
points published in Annals of Internal Medicine that 
provide guidance for non-pregnant, non-immuno-
compromised adults.4
The practice points, which apply to adults 60 years 
and older, draw a distinction between two age brack-
ets. Adults 75 and older should receive an RSV vac-
cine, the ACP concluded. For adults 60 to 74 who are 
at increased risk for severe RSV, ACP suggests that 
vaccination may be considered. 
The practice point team was led by the American 
College of Physicians in Philadelphia and included 
participation from University of Minnesota School 
of Medicine and Public Health and Minneapolis, 
MN, VA Health Care System and the Portland, OR, 
VAMC and Oregon Health & Science University, 
Portland, Oregon (L.L.H.).
The authors urged clinicians to be aware that 
institutional guidance might vary, and that shared 
	
	
2 0 2 6  C O M P E N D I U M  O F  F E D E R A L  M E D I C I N E  
7 7
Durability of Respiratory Syncytial Virus Vaccine Effectiveness Among US Veterans
Source: JAMA Intern Med. 2026;186(1):78-88. doi:10.1001/jamainternmed.2025.6355

View this content as a flipbook by clicking here.